Ambrx Is A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Protein Therapeutics Through An Expanded Genetic Code Technology Platformfounded In 2003 And Based In The United Statesambrx Utilizes Technology Developed By Uc Berkeley Chemistry Professor Peter Schultzthe Company Has Strong Support From Chinese Venture Capital Firms And Has Made Significant Advancements In Antibody Drug Conjugatesadcsand Bio Conjugates Ambrx S Core Technology Allows For The Incorporation Of Synthetic Amino Acids Into Proteinsenabling Precise And Stable Conjugationthis Enhances The Therapeutic Functions Of Adcs And Supports The Development Of Long Acting Proteins And Bispecificsthe Company Is Advancing A Portfolio Of Clinical And Preclinical Programsincluding Arx517An Adc Targeting Prostate Cancerand Arx788An Adc Targeting Her2Which Is Currently In Phase I Trials In Addition To Its Innovative Productsambrx Has Formed Partnerships To Further Its Drug Development Effortsthe Company Went Public On The Nasdaq In 2021 And Was Added To The Nasdaq Biotechnology Index In December 2023Highlighting Its Growing Influence In The Biotech Industry
